[A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation].

Levodopa remains a 'gold standard' for the treatment of patients with Parkinson's disease (PD), but its chronic use is accompanied by fluctuations of symptoms and dyskinesias related to unfavorable pharmacokinetics of levodopa and progressing loss of the nigrostriatal neurons. Prescribing inhibitors of catechol-O-methyl-transferase (enzyme of dopamine metabolism), entacapone or tolcapone, is a perspective approach to the correction of the above-mentioned complications. We followed up 402 patients with PD who received long-term therapy with a combined preparation Stalevo (levodopa/carbidopa/entacapone) for 2-5 years (2.

[Mexidant increases the effectiveness of levadopa treatment of Parkinson's disease].

The efficiency of mexidant therapy in patients with Parkinson's disease (PD) has been evaluated. The study included 49 patients aged 58-65 with a trembling-rigid and trembling forms of PD at an disease duration of 6.5 +/- 3.

[Method of preparation of tissue engineering and cell cultivation collagen by acid extraction of calf skin].

Seven methods of preparation of intact native collagen with telopeptides by acid extraction of calf skin have been compared; the hide was first dehaired by original mild enzymatical method using Bacillus licheniformis protease. The noncollagenous proteins and proteoglycans were previously removed by different ways and collagen was extracted by acid solvents and purified by salt precipitation. The dynamic of noncollagen impurities removing was followed by noncollagen proteins and hexuronic acids analysis in extracts.

[Experience with application of trospium chloride in patients with neurogenic detrusor overactivity].

Overactive bladder (OAB) is observed in such brain diseases as stroke, hypoxic ischemic encephalopathy, Parkinson's disease (PD), multiple sclerosis (MS). Trospium chloride (spasmex) was used in OAB patients with MS (n = 87), stroke (n = 83), encephalopathy (n = 47) and PD (n = 36) in doses from 15 to 45 mg/day in 2 to 36 month courses. The response with minimal side effects was achieved in 94% patients.

[7-year experience in usage of mirapex in patients with different forms of primary parkinsonism].

The results of mirapex (pramipexol) treatment of 402 patients with Parkinson's disease and juvenile parkinsonism during the period from 6 months to 7 years are summarized. Mirapex was used in monotherapy as well as in combination with levadopa and other antiparkinsonic drugs. The drug was well tolerated and effective in rest tremor, hypokinesia, muscle rigidity and depression, the more pronounced effect being seen at the early stage of the disease.

[Cytochemical activity of mitochondrial enzymes in Parkinson's disease].

Using cytochemical computerized morphometric method, activity of the key enzymes of energetic metabolism (succinate dehydrogenase, alpha-glycerophosphate dehydrogenase, malate dehydrogenase, glutamate dehydrogenase and lactate dehydrogenase) was studied in blood lymphocytes of 75 patients with Parkinson's disease and 15 healthy controls. The signs of systemic mitochondrial insufficiency, which correlated with the disease duration and severity, were found in all the patients, including those with juvenile parkinsonism. These data may provide a basis for introducing cytochemical monitoring as well as for administration of modern "mitochondrial" drugs (yantavit, coenzyme Q10, L-carnitine, etc).

[Modelling of myocardial hypertrophy in vitro for solving problems of medicinal correction].

The work has been done on primary heart culture from neonatal rat ventricle. Cardiomyocyte hypertrophy was modelled using noradrenaline (NA), angiotensin II (AII) and fetal serum, respectively. Cell hypertrophy of primary heart cultures was assessed by measuring the surface area, the scope of protein synthesis estimated by 3H-leucine autoradiography and the contents of nucleic acids in gallocyanin-chromalum stained cardiomyocytes.

[Correlation between expression of antigen immunologically related to gp52 MMTV and transcription of homologous ENV MMTV DNA sequences in peripheral blood lymphocytes from breast cancer patients].

Previously we reported that HMCAg related to gp52, env product of MMTV, was a specific marker of human breast cancer (BC). This antigen was expressed not only in BC tissue and patients' sera, but in peripheral T- and B-cells. HMCAg was found in 21.

[Tumor-induced immunosuppression in breast cancer patients].

A comparative study of immunological reactivity of healthy volunteers and cancer patients with different stages of the disease was carried out. The study of 8 types of suppressor cells, chemoreceptor sensitivity and blast transformation of lymphocytes, natural killer cells, the level of immunoglobulins, regulatory subpopulation of lymphocytes, etc., has revealed several alterations in regulatory and effector links of immunity in the patients with late stages of the disease.

[Disorders of the immune system in benign lesions and cancer of the breast].

Immunologic vigor was studied in 225 cases of breast cancer at various stages, 99 patients with benign lesions of the breast and 154 healthy donors. The parameters of cell-mediated immunity under study included total, active and neuraminidase T-lymphocyte levels, concentration of T-lymphocyte subsets (Tm, T gamma, theophylline--sensitive and theophylline--resistant) and their profile, functional activity of lymphocytes in blastogenic reaction with PHA and natural killer levels. Also, such humoral immunity indexes as B-lymphocytes and immunoglobulins A, M and C were evaluated.

[Histamine-receptor sensitivity of lymphocytes in patients with early and advanced stage breast cancer].

It is established that histamine in the concentration of 10(-4)-10(-5) M possesses an inhibitory effect in the lymphocyte adherence inhibition test in patients with breast cancer. Using specific antagonists (H1-blocker dimedrol and H2-blocker cimetidine) it is shown that the revealed histaminergic suppression of the lymphocyte adherence inhibition is mediated through the stimulating influence of histamine on H2-receptors.

[Immunotherapy with decaris in the early stages of breast cancer].

A randomized clinical study of adjuvant immunotherapy with decaris was carried out in patients with early breast cancer. 92 patients with stages I and IIA tumors (T1,2N0M0) received 300 mg decaris weekly (150 mg for 2 successive days) 2 weeks after radical mastectomy (Patey) used as a sole preventive therapy. The short (1 month) (group I), the medium (3 months) (group 2) and the long-term intermittent (three 3 month courses during 15 months) (group 3) modalities were compared.

[Changes in sensitivity of lymphocyte cholinergic receptors in patients with breast cancer].

Alteration of the cholinoreceptor sensitivity of peripheral blood lymphocytes in patients with breast cancer was studied by the lymphocyte adhesion inhibition test (LAI-test). It has been shown that acetylcholine stimulates the LAI-reaction in optimal concentrations of 10(-7)-10(-8) M. Specific antagonists (m-cholinoblocker of atropin and n-cholinoblocker of hexonium) being used, it is demonstrated that the revealed cholinergic enhancement of the lymphocyte adherence inhibition is mediated through the stimulating influence of acetylcholine on m-cholinoreceptors.

[Study of the participation of the alpha-chain of the LFA-1 antigen in the phenomenon of lymphocyte adherence inhibition using ICO-11 monoclonal antibodies in vitro].

The influence of monoclonal antibodies (Mabs) ICO-11 on the ability of lymphocytes from breast cancer patients to react in lymphocyte adherence inhibition (LAI) test has been studied in vitro. It has been demonstrated that Mabs ICO-11 in the dilutions 1/4 and higher blocked the reaction to tumor extracts in LAI-test, without affecting the reaction to the extracts of normal tissues and a spontaneous adhesion of lymphocytes of healthy donors as well. The addition of the control supernatants of myeloma cells X63.

[Relation of blood serum ferritin and ferritin-bearing lymphocytes in breast cancer].

The ratio of the blood serum ferritin level and the amount of ferritin-bearing lymphocytes was determined in breast cancer patients and mastopathy patients. Direct relation between a rise of blood serum ferritin concentration, a drop in the amount of ferritin-bearing cells and tumor spreading was established in breast cancer. The maximum amount of ferritin-bearing cells was present in the blood of the patients with Stage I-IIA disease.

[Stimulation of the immunological reactivity of cancer patients by Eleutherococcus extract].

In vitro treatment of lymphocytes with eleutherococcal preparation produced an immune-boosting effect both in cancer patients and healthy controls. The results of a randomized study pointed to eleutherococcus' capability of stimulating general non-specific resistance and immunologic vigor in the course of cytostatic and radiation treatment for breast cancer. Since eleutherococcus is free of toxicity and allergenicity in prolonged treatment, it is indicated in patients receiving intensive antitumor therapy.

[Morphological and immunologic changes following intratumoral administration of alpha interferon in patients with breast cancer].

Patients with early breast cancer received single intratumoral injections of 10,000, 100,000 or 200,000 IU alpha-interferon before radical surgery. Interferon was found to produce a dose-dependent cytotoxic and immune-boosting effect. A dose of 100,000 and 200,000 IU caused drug pathomorphosis in tumor and brought down immunologic indexes of peripheral blood.